MiNK Showcases AgenT-797 in Severe ARDS Transplant Patient at ATS Meeting

NEW YORK, May 22, 2024 – MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical enterprise, recently presented clinical data on agenT-797 at the American Thoracic Society (ATS) Annual Meeting. The focus was on a critical case of severe acute respiratory distress (ARDS). This data adds to a growing body of evidence supporting the clinical activity of agenT-797 in patients suffering from severe ARDS.

Dr. Terese Hammond from the University of California Los Angeles commented on the findings, stating that the observed improvement in this case supports the potential efficacy of allogeneic iNKT cells in treating severe respiratory distress. The need for new therapeutic options is pressing, especially for immune-compromised individuals facing respiratory difficulties. According to Hammond, the expanding data set indicates that iNKTs may play a significant role in treating acute critical illnesses, warranting further exploration.

Clinical Findings

The patient in this study was a 26-year-old who had undergone a renal transplant and was chronically immunosuppressed. After contracting COVID-19, the patient progressed to severe hypoxemic respiratory failure and required veno-venous extracorporeal membrane oxygenation (VV-ECMO).

On the 13th day of hospitalization, the patient received a single dose of 1x10^9 allogeneic iNKT cells (agenT-797). Following this treatment, there was a rapid reduction in inflammatory cytokines, including IL-18, which is consistent with data from the Phase 1 trial of agenT-797 in COVID-19 ARDS. The patient was extubated on the 37th day and discharged from the hospital on the 60th day. Remarkably, within six months post-dosing, the patient was weaned off hemodialysis and had resumed normal daily activities.

About MiNK Therapeutics

MiNK Therapeutics is at the forefront of the biopharmaceutical industry, focusing on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies. These therapies aim to treat cancer and other immune-mediated diseases. The company is advancing a range of both native and engineered iNKT programs, supported by a platform designed to ensure scalable and reproducible manufacturing for off-the-shelf delivery. Based in New York, NY, MiNK Therapeutics continues to push the boundaries of cell therapy. For more information, visit their website.